Docetaxel for the treatment of hormone-refractory metastatic prostate cancer

NICE technology appraisals [TA101] Published date:

Docetaxel is recommended as a possible treatment for men with hormone-refractory metastatic prostate cancer.

  • It should be given only if the man is well enough to care for himself with occasional assistance.
  • Treatment should be stopped at the end of a planned course of up to 10 cycles (or 'rounds') of docetaxel.
  • The treatment should be stopped early if the man experiences serious side effects, or if the disease is getting worse.

NICE does not recommend using docetaxel again if the disease comes back after the first course of treatment has finished.

Get involved